T his study demonstrates a novel gene therapy method for targeting vaccinating autologous tumor cells to antigen-presenting cells (APC), thereby increasing the immunogenicity of the vaccinating cells. Immunotherapy in cancer patients in remission is aimed to elicit an immune response against autologous tumor-associated antigens (TAA), in order to destroy tumor cells expressing these antigens in micrometastases, or as minimal residual disease in hematological malignancies. Whereas many TAA have been identified in patients with melanoma, 1 in most types of tumors, the identity of various TAA is unknown as yet. Therefore, autologous tumor cells have been viewed as a suitable source of immunizing TAA. [2] [3] [4] [5] The possible use of uncharacterized autologous TAA as vaccine has been supported by studies demonstrating that immunization with APC pulsed in vitro with peptides eluted nonspecifically from tumors, or with APC fused with tumor cells, resulted in the subsequent induction of a protective immune response against the tumor.
6-8 However, studies for almost 100 years on in vivo immunization with unmodified autologous tumor cells have demonstrated a very limited therapeutic success. Poor uptake of vaccinating tumor cells by APC has been considered as a major reason for the low immunogenicity of unmodified autologous tumor vaccines. [9] [10] [11] Tumor cells in cancer patients develop in a ''stealthy way'', so they are not recognizable by APC as cells that have to be internalized and their TAA processed. 12, 13 The effective uptake of vaccinating tumor cells by APC at the vaccination site is a prerequisite for successful tumor vaccines. This is because APC have to transport the vaccine from the vaccination site to the draining lymph nodes, where TAA are processed by the APC and TAA peptides are presented on the APC in association with class I or class II MHC molecules, for the activation of tumor-specific cytotoxic and helper T cells, respectively. [9] [10] [11] [12] [13] Only after they are activated, the tumor-specific T cells can leave the lymph nodes and circulate in the body in order to seek and destroy tumor cells expressing these TAA. [9] [10] [11] [12] [13] Since APC, including macrophages, skin Langerhans cells and dendritic cells, all express Fcg receptors for IgG molecules, [14] [15] [16] effective uptake and internalization of vaccines by APC may be achieved by complexing the vaccine with an IgG antibody (i.e. opsonization) and the subsequent targeting of the vaccine to APC. This targeting is the result of the interaction between the Fc portion of the vaccine-bound IgG molecules and Fcg receptors on APC. Moreover, binding of immune complexes to Fcg receptors of dendritic cells was found to induce effective maturation of the dendritic cells, resulting in crosspresentation of the antigenic peptides by class I MHC molecules for the activation of CD8 þ cytotoxic T cells, as well as presentation of peptides on class II MHC molecules for the activation of CD4 þ helper T cells. [17] [18] [19] Increased immunogenicity of vaccines as a result of targeting to APC by complexed IgG antibodies is a phenomenon which has been observed with bacterial vaccines (e.g. tetanus toxoid [20] [21] [22] ), viral vaccines (e.g. hepatitis B 23, 24 and Simian immunodeficiency virus 25 ) and protozoan vaccine (e.g. Leishmania
26
). Natural antibodies in mice were found to function with the latter vaccine as endogenous adjuvant that increases immune response against intracellular Leishmania parasites. 26 We previously proposed that this type of in vivo antibody-mediated targeting of autologous tumor vaccines to APC may be achieved in humans by exploiting the natural anti-Gal antibody as an endogenous adjuvant. [27] [28] [29] Anti-Gal is the most abundant natural IgG antibody in humans, constituting B1% of circulating immunoglobulins in all humans that are not severely immunocompromized. 30 Anti-Gal interacts specifically with the a-gal epitope (Gala1-3Galb1-4GlcNAc-R), a carbohydrate epitope abundantly produced on glycoproteins and glycolipids of non-primate mammals and New World monkeys by the glycosylation enzyme a1,3galactosyl-transferase (a1,3GT). [31] [32] [33] [34] We and others found that the a-gal epitope is absent, however, in Old World monkeys, apes and humans, because of evolutionary inactivation of the a1,3GT gene in ancestral Old World primates. [34] [35] [36] [37] As an outcome of these evolutionary differences, anti-Gal functions in vivo as a major barrier for xenotransplantation of pig organs in humans, as its binding to a-gal epitopes on pig xenograft cells induces rapid rejection of the graft. [38] [39] [40] [41] We hypothesized that vaccination with human autologous tumor cells, processed to express a-gal epitopes, will result in a similar in vivo binding of anti-Gal IgG molecules to these epitopes on the vaccinating cells. [27] [28] [29] Since all APC express Fcg receptors, [14] [15] [16] the interaction between the Fc portion of anti-Gal bound to a-gal epitopes on vaccinating tumor cells and Fcg receptors on APC is likely to induce a very effective uptake (i.e. phagocytosis) and processing of these tumor cells by the various APC. This hypothesis is supported by our observations on a 10-fold increase in the activation of T cells specific to an APC-processed peptide of influenza virus hemagglutinin, when the virus expressing a-gal epitopes bound anti-Gal prior to APC uptake. 42 In fact, anti-Gal is the only known human natural antibody that may be exploited as an endogenous adjuvant for targeting vaccines to APC, as there are no other natural IgG antibodies with defined specificity, known to be present in large amounts in all humans.
In previous studies, we demonstrated the synthesis of a-gal epitopes on human tumor cells, or on tumor cell membranes by the use of recombinant a1,3GT, and the subsequent in vitro anti-Gal-mediated phagocytosis of such cells by human macrophages and dendritic cells. 27, 28, 43, 44 We hypothesized that increased immunogenicity of autologous tumor vaccines by anti-Gal targeting to APC may be achieved by gene therapy methods for de novo expression of a-gal epitopes on vaccinating tumor cells. In the present study, we addressed in an experimental animal model, three questions associated with such targeting by gene therapy: (1) can we achieve expression of a-gal epitopes on vaccinating tumor cells by transduction with replication deficient adenovirus containing the a1,3GT gene (AdaGT), ( 2) can we demonstrate in vivo anti-Gal-mediated targeting to APC of autologous cells expressing a-gal epitopes, and (3) can AdaGT-transduced tumor cells function as a vaccine that protects against a challenge with the same tumor cells, which however, lack a-gal epitopes. We used the experimental animal model of a1,3GT knockout (KO) mouse 45 to study these questions. The KO mice simulate the relevant human immune parameters in that they are the only non-primate experimental animal model that lacks a-gal epitopes because of the disruption of the a1,3GT gene. 45 Since the a-gal epitope is absent in KO mice, they ceased to be immunotolerant to it and can produce the anti-Gal antibody when immunized with xenogeneic membranes expressing a-gal epitopes such as rabbit red cell membranes. 46 In contrast, wild-type (WT) mice express a-gal epitopes and cannot produce anti-Gal. 34, 47 Since all available mouse tumor cell lines originate from WT mice, most of them express a-gal epitopes, 34 and thus are destroyed in KO mice by circulating anti-Gal in a manner similar to anti-Gal-mediated rejection of xenografts. 47, 48 However, we have found that the mouse BL6 melanoma cells (a highly tumorigenic subclone of B16 melanoma [49] [50] [51] ), which express H-2b as the KO mouse, completely lack a-gal epitope. 49, 50 Since human tumor cells also are selected in vivo to be highly tumorigenic 12, 13 and since they all lack a-gal epitopes, 
Materials and methods

Mice, tumor cells and materials
Mice used were a1,3GT KO mice on H-2bxd background. 45 Studies were performed with both males and females, and found to yield similar results. The mice were immunized three times with rabbit red cell membranes for inducing anti-Gal production in titers similar to those of anti-Gal in humans (titers of 1:200 to 1:2000 as measured by ELISA with a-gal BSA (synthetic a-gal epitopes linked to bovine serum albumin)). 28, 46 The tumor cell line used was B16-BL6 melanoma (referred to as BL6), which is a highly tumorigenic subclone of B16 melanoma. [49] [50] [51] The monoclonal anti-Gal antibody designated M86 was obtained in tissue culture supernatants of the hybridoma M86 cells, as we described previously. 52 Horseradish-peroxidase (HRP)-conjugated anti-mouse IgM and anti-mouse IgG were purchased from Accurate Laboratories (Westbury, NY); fluorescein (FITC)-conjugated anti-mouse IgG was purchased from Pharmingen (San Diego, CA); FITC-conjugated Bandeiraea (Griffonia) simplicifolia IB4 (BS lectin -specific for a-gal epitopes) was purchased from Vector Laboratories (Burlingame, CA); and a-gal BSA was purchased from Dextra Laboratories (Reading, UK).
Synthesis of a-gal epitopes on mouse red cells KO mouse red blood cells (MRBC) were fixed with 0.5% glutaraldehyde and blocked with 0.1 M glycine in order to track them following their in vivo uptake by APC. Subsequently, the washed MRBC were subjected to synthesis of a-gal epitopes by incubation with neuraminidase and with recombinant a1,3GT, as we have described previously. 28, 53 Briefly, 1 Â 10 9 red cells/ml were incubated with 1 mU/ml neuraminidase (Sigma, St Louis, MO) and 50 mg/ml recombinant a1,3GT cloned from New World monkey cells and produced in our lab in the yeast Pichia pastoris expression system. 54 As sugar donor, we used 1 mM UDP-Gal. The enzyme buffer contained saline, 25 mM MES and 25 mM MnCl 2 , pH 6.2. Expression of a-gal epitopes on the processed MRBC was confirmed by the binding of anti-Gal within the serum of KO mouse (diluted 1:10) followed by FITC-anti-mouse IgG and flow cytometry analysis (FACSCalibur flow cytometer, Becton Dickinson, San Jose, CA).
Induction of macrophage accumulation in the peritoneal cavity of KO mice KO mice were injected into the peritoneal cavity with 1 ml of 10 mg/ml thioglycolate. This results in the accumulation of macrophages in the peritoneal fluid within a period of 72 hours. Subsequently, the mice received intraperitoneally 5 Â 10 8 MRBC that were processed to express a-gal epitopes (MRBC agal ). After 20 hours, 10 ml PBS were injected into the peritoneal cavity and allowed to mix for 5 minutes with the peritoneal fluid. Subsequently, 10 ml cell suspensions were removed from the peritoneal cavity and the amount of MRBC determined by microscopic counting. The macrophages in the peritoneal wash were subjected to Wright staining and viewed microscopically. The control group included KO mice receiving glutaraldehyde-fixed original MRBC that lack a-gal epitopes.
Transduction of BL6 cells by AdaGT
The adenovirus vector AdaGT, containing the open reading frame (ORF) of the mouse a1,3GT gene, was produced as we described previously. 55 AdaGT was propagated in 293 cells and used for transduction at a concentration of 1 Â 10 10 infectious units (IU)/ml. BL6 cells were incubated with AdaGT for 4 hours at 371C. Subsequently, culture medium (DMEM supplemented with 10% fetal bovine serum) was added to dilute the AdaGT suspension five-fold and cell monolayers were incubated for 48 hours. For immunization, the cells were detached by 1 mM EDTA in PBS, washed and irradiated with 50Gy, a dose that kills 100% of the cells. These cells were referred to as BL6 AdaGT cells. BL6 cells transduced with ''empty'' control adenovirus 56 that lacks the a1,3GT insert are referred to as BL6 controlAd cells.
PCR analysis of transduced cells for a1,3GT DNA and mRNA
The a1,3GT gene within the transducing AdaGT was detected in BL6 cells as previously described 55 by PCR of the ORF of this gene 57 (40 cycles each including 30 seconds at 941C, 30 seconds at 531C and 1 minute at 721C), with the upstream primer 5 0 ATGAATGT CAAGGGAAAAG3 0 and the downstream primer 5 0 TCAGACATTATTTCTAACCA3 0 . These primers, yielding a 1080 bp DNA product, do not amplify the mouse a1,3GT gene within BL6 cell DNA, since they are on different exons. 58 For identifying a1,3GT mRNA in the transduced cells, the RNA was extracted, contaminating DNA destroyed by DNase, cDNA produced with random hexamers and PCR followed with the primers above.
Flow cytometry analysis of a-gal epitope expression on transduced BL6 cells BL6 cells were incubated at a concentration of 1 Â 10 6 cells/ml for 1 hour at 41C with 10 mg/ml FITC-labeled Bandeiraea (Griffonia) simplicifolia IB4 (FITC-BS lectin) in PBS containing 1% BSA. This lectin binds specifically to a-gal epitopes on cells. 59 Cells were then washed three times with PBS, fixed and analyzed in the flow cytometer.
Quantification of a-gal epitope expression on transduced BL6 cells by the ELISA inhibition assay
Quantification of a-gal epitopes de novo expressed on transduced cells was performed by the ''ELISA inhibition assay'', in which the number of a-gal epitopes per cell could be determined by binding of the monoclonal antiGal antibody M86. 52, 55 The assayed cells were brought to
In vivo targeting of vaccinating tumor cells L Deriy et al a concentration of 40 Â 10 6 cells/ml and subjected to serial two-fold dilutions in 100 ml aliquots of PBS containing 1% BSA. The cells in each dilution were mixed with equal volume of monoclonal anti-Gal M86 antibody at the final dilution of 1:100, that is, a concentration of the antibody that yields ELISA absorbance results at the slope of the binding curve of M86 to a-gal BSA. The mixture of cells and M86 monoclonal anti-Gal was incubated overnight at 41C with constant rotation to enable maximum binding of the antibody to a-gal epitopes. Subsequently, the cells with bound M86 IgM molecules were removed by centrifugation and the activity of free M86 remaining in the supernatant was determined by ELISA with a-gal BSA as solid-phase antigen, using HRP-conjugated goat anti-mouse IgM antibody as secondary antibody. Cells expressing a-gal epitopes bind the antibody proportionally to the number of a-gal epitopes expressed on them. Therefore, the amount of free M86 antibody remaining in the supernatant is inversely proportional to the number of epitopes per cell. By comparing the binding of M86 to cells with known number of a-gal epitopes per cell (standard cells), to that of the antibody binding to the assayed cells, it is possible to determine the average number of a-gal epitopes per cell. Rabbit red cells were used as the standard cells because they were previously shown to express 2 Â 10 6 a-gal epitopes per cell. 52 
ELISA for anti-Gal binding to a-gal epitopes on transduced cells
Suspensions of transduced BL6 cells (BL6 AdaGT or BL6 controlAd cells) at 2 Â 10 6 cells/ml in PBS were dried as 50 ml aliquots in ELISA wells. This results in firm adhesion of the cells to the ELISA wells, 27, 5, 55 which were subsequently blocked with 1% BSA in PBS. Mouse serum containing anti-Gal was added at various dilutions to the wells for 2 hours. Subsequently, the plates were washed and color developed after incubation with HRP-coupled anti-mouse IgG. The OD measured in ELISA with nontransduced parental BL6 cells was subtracted at each antibody dilution to prevent measuring nonspecific antibody binding.
Immunization and challenge of mice with tumor cells
Mice that were confirmed for the production of anti-Gal IgG in titers similar to those found in humans were immunized subcutaneously in the left abdominal flank with 2 Â 10 6 BL6 controlAd cells (control group), or with BL6 AdaGT cells (experimental group). The immunizing cells were irradiated with 50 Gy prior to immunization. The immunization was repeated at the same site after 1 week. At 1 week after the second immunization, the mice were challenged with 2.5 Â 10 5 or 5.0 Â 10 5 nontransduced live BL6 cells, as indicated. The challenge was performed subcutaneously in the right flank. The development of the tumor was monitored daily for 60 days. Positive subcutaneous tumor growth was determined as tumor with a size of Z5 mm.
Results
Transduction of BL6 cells by AdaGT
Previous studies aimed to de novo express a-gal epitopes on tumor cell lines used vectors containing the a1,3GT gene such as plasmids and retroviruses, which required the subsequent subcloning of proliferating cells that display stable expression of this epitope. 50, [60] [61] [62] [63] Freshly isolated tumor cells that are to be manipulated in a clinical setting to serve as an autologous tumor vaccine expressing a-gal epitopes, are mostly cells that are nondividing in vitro. Expression of these epitopes on nondividing tumor cells may be achieved by transduction with replication defective adenovirus containing the a1,3GT gene. For this purpose, we have generated such an adenovirus (designated AdaGT), by inserting the open reading frame (ORF) of the mouse a1,3GT gene into the region of the missing E1 gene of the WT virus. 55 In the present study, we first determined the ability of AdaGT to induce expression of a-gal epitopes on the mouse melanoma BL6 cells that serve as the tumor model for the autologous tumor vaccine. These tumor cells differ from most other mouse tumor cell lines in that they do not express a-gal epitopes because of the inactive a1,3GT gene, whereas other mouse tumor cells express a-gal epitopes due to constitutive expression of this gene. 34, 49, 50, 64 The lack of a1,3GT gene expression in BL6 cells is also demonstrated in Figure 1 , in which the presence and expression of this gene was evaluated in nontransduced and transduced BL6 cells by PCR and RT-PCR of the 1080 bp ORF. As expected, the original nontransduced BL6 cells do not include a template for PCR, since the a1,3GT gene is comprised of several exons 58 (lane 1). RT-PCR of a1,3GT mRNA was also found to be negative in 56 ) lacked any a1,3GT mRNA template (lane 4). It should be stressed that in all RT-PCR studies, the RNA preparations were treated with DNase to digest any viral DNA and confirmed to lack any DNA template by negative PCR results without the use of reverse transcriptase (not shown).
Expression of a-gal epitopes on BL6 cells transduced with AdaGT
Expression of a-gal epitopes on AdaGT-transduced cells, as a result of their de novo synthesis by the viral a1,3GT, was evaluated 48 hours post-transduction by three independent methods including: (1) binding of lectin Bandeiraea (Griffonia) simplicifolia IB4 (BS lectin), which interacts specifically with a-gal epitopes on cells, 59 (2) binding of monoclonal anti-Gal and (3) binding of KO mouse serum anti-Gal. First, BL6 cells transduced with AdaGT (referred to as BL6 AdaGT cells) displayed a significant shift following BS lectin binding, as measured by flow cytometry, in comparison to BL6 controlAd cells (Fig 2a) . In addition, B15% of the BL6 AdaGT cells displayed a much higher degree of lectin binding than the rest of the population, indicating that these cells express a-gal epitopes in high numbers.
In order to determine the average number of a-gal epitopes expressed de novo on BL6 AdaGT cells, the transduced cells were subjected to the ELISA inhibition assay with the monoclonal anti-Gal antibody M86. 52, 55 As described in the Materials and methods section, the extent of M86 binding to cells is proportional to the number of a-gal epitopes per cell. This binding of M86 to a-gal epitopes on cells is inferred from the subsequent 
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decrease in the activity of M86 remaining in the solution, after the removal of cells with bound M86. This decrease in M86 activity (% inhibition of M86 binding) was determined by ELISA with a-gal BSA as solid-phase antigen. 52 As shown in Figure 2b , BL6 controlAd cells bound no M86 antibody even at a concentration of 40 Â 10 6 cell/ ml (i.e. 0% inhibition). This finding is in accord with the complete lack of a-gal epitopes on these cells. 49, 50 However, BL6 AdaGT cells bound M86 and displayed 50% inhibition of M86 binding at a concentration of 5 Â 10 6 cells/ml. This concentration is B4-fold higher than that required for rabbit red cells to display 50% inhibition. Since rabbit red cells express B2 Â 10 6 a-gal epitopes/cell, 52 BL6 AdaGT cells express four-fold lower number of a-gal epitopes, that is, B0.5 Â 10 6 epitopes/ cell. This number of a-gal epitopes expressed on BL6 AdaGT cells was found to be highly reproducible, as similar data were obtained in five individual experiments in which BL6 cells were transduced with 1 Â 10 6 infectious units (IU)/ml of AdaGT (not shown).
We could further demonstrate by ELISA the ability of mouse anti-Gal IgG to bind to the a-gal epitopes on BL6 AdaGT cells (Fig 2c) . The production of anti-Gal in KO mice was induced by immunization of the mice with rabbit red cell membranes (i.e. xenogeneic membranes expressing an abundance of a-gal epitopes). 33, 46 The specificity of the serum anti-Gal in binding to the de novo expressed a-gal epitopes on the transduced cells was confirmed by the lack of antibody binding in wells containing BL6 controlAd cells as solid-phase antigen (Fig 2c) .
In vivo anti-Gal-mediated targeting of mouse red cells expressing a-gal epitopes to APC
We hypothesize that vaccination of KO mice with AdaGT-transduced tumor cells (i.e. BL6 AdaGT cells) is likely to result in in vivo opsonization of these cells by anti-Gal IgG molecules that bind to the a-gal epitopes and target the vaccinating tumor cells to APC. Visualization of the in vivo phagocytosis of anti-Gal-opsonized tumor cells by APC is technically difficult since the vaccinating tumor cells, which are of a size similar to that of the APC, disintegrate during the process of phagocytosis by APC. We could demonstrate, however, in vivo anti-Gal-mediated targeting of smaller autologous cells processed to express a-gal epitopes, by the use of glutaraldehyde-fixed autologous red cells instead of tumor cells. The fixation was performed in order to prevent the lysis of red cells by anti-Gal and complement and to delay intracellular destruction of the red cells within APC, thus allowing for morphological studies. KO MRBC were processed to express a-gal epitopes (MRBC a gal) by the use of recombinant a1,3GT.
28,43,44,53,54 MRBC agal readily bound anti-Gal IgG when incubated with serum from anti-Gal-producing KO mice, as demonstrated by flow cytometry (Fig 3) . In contrast, unprocessed MRBC displayed only marginal nonspecific binding of serum IgG, as they completely lack a-gal epitopes (Fig 3) . It should be stressed that expression of a-gal epitopes on MRBC could not be achieved by transduction with AdaGT, as used above for BL6 cells, since red cells lack the Golgi apparatus required for the activity of endogenous a1,3GT.
Anti-Gal-producing KO mice (i.e. mice immunized with rabbit red cells 46, 65 ) received intraperitoneally 5 Â 10 8 MRBC agal 3 days after intraperitoneal thioglycolate injection for inducing accumulation of macrophages as APC. The control group of mice received 5 Â 10 8 unprocessed MRBC lacking a-gal epitopes. After 20 hours, the peritoneal cavity was washed with 10 ml PBS and the red cells were counted in the wash. In control mice, 120 Â 10 6 to 200 Â 10 6 of unprocessed MRBC (25-40% of the injected red cells) were retrieved in the wash (mice #6-10 in Fig 4a) . However, in mice receiving MRBC agal , most of these red cells were phagocytozed by macrophages within 20 hours. This is indicated by the finding that only 3 Â 10 6 to 10 Â 10 6 of the red cells (0.6-2% of the injected red cells) were retrieved from the peritoneal cavity (mice #1-5 in Fig 4a) . This extensive in vivo uptake of anti-Gal-opsonized MRBC agal could be further demonstrated in stained macrophages within the peritoneal wash. Almost all stained macrophages contained several (3-12) MRBC agal . A representative macrophage from this wash, containing seven MRBC agal , is shown in Figure 4b . In contrast, macrophages in the control group of mice receiving unprocessed MRBC displayed no uptake of red cells, as demonstrated in the representative macrophage in Figure 4c . It is probable that although only 25-40% of MRBC were retrieved in the control mice, many of the red cells remained in the peritoneal fluid that was not removed from the mice in the wash. Overall, these data demonstrate the effective in vivo anti-Gal-mediated targeting of cells expressing a-gal 
Vaccination with BL6 AdaGT cells protects against challenge with parental BL6 tumor cells
The observations above on the in vivo targeting of MRBC agal to APC suggested that similar anti-Galmediated targeting may be achieved in vivo with BL6 AdaGT cells that would be effectively internalized by APC. We hypothesized that such targeting may elicit a protective antitumor immune response. To study the effect of AdaGT transduction on immunogenicity of vaccinating tumor cells, BL6 cells transduced with AdaGT (BL6 AdaGT ), or with control ''empty'' adenovirus (BL6 controlAd ), were cultured for 48 hours and irradiated with 50 Gy. Anti-Gal-producing KO mice were immunized subcutaneously in the left flank, twice in 1 week interval, with 2 Â 10 6 irradiated BL6 AdaGT cells, or with 2 Â 10 6 BL6 controlAd cells. At 1 week after the second immunization, the mice were challenged subcutaneously at the right flank with 2.5 Â 10 5 live parental BL6 cells that lack the a-gal epitope. Subsequently, the mice were monitored for 60 days for tumor development. Tumor growth was considered positive if the developing subcutaneous melanoma reached a size of Z5 mm. As many as 64% (14 out of initial number of 22 mice) of those inspected 60 days posttumor challenge were found to be tumor free in the experimental group immunized with BL6 AdaGT cells (Fig 5) . In contrast, only 33% of the mice in the control group immunized with BL6 controlAd cells (seven out of 21 mice) were tumor free for 60 days postchallenge (Fig 5) . The rate of tumor growth in BL6 AdaGT -vaccinated mice that developed tumors appeared to be slower than that in mice vaccinated with BL6 controlAd cells. This was inferred from the period required for tumors to achieve a size of B5 mm in equal proportions of the mice in the two groups. Whereas onethird of the mice in the experimental group developed tumors within 30 days, one-third of the mice in the control group developed tumors already within 22 days postchallenge.
The lack of tumor growth in a third of the control mice (Fig 5) implied that the tumor burden in the challenge of 2.5 Â this challenge, all eight mice in the control group (i.e. mice immunized with BL6 controlAd cells) developed tumors within 26 days (Fig 6a) . However, in the experimental group of mice immunized with BL6 AdaGT cells, four out of 11 mice studied remained tumor free until the end point of the experiment, 60 days postchallenge (Fig 6a) . The difference in the starting number of mice in the two groups was the result of accidental death prior to challenge with live tumor cells. In order to further confirm these observations, this vaccination and challenge study was repeated in larger groups that included 18 mice in the control group and 21 in the experimental group (Fig 6b) (Fig 6b) . The tumor-free mice were monitored for additional 30 days (beyond the 60 days period) and were found to display no tumor growth (not shown). This suggests that mice that do not display tumor growth 60 days postchallenge are very likely to be tumor free. Overall, these observations strongly suggest that immunization with BL6 AdaGT cells is much more effective than immunization with BL6 cells lacking a-gal epitopes, in eliciting a protective antitumor response.
Discussion
The present study demonstrates a novel gene therapy method that exploits the natural anti-Gal antibody as an endogenous adjuvant capable of targeting autologous tumor vaccines to APC. The study is performed in an experimental animal model of KO mice that, like humans, lack the a-gal epitope and produce anti-Gal. The BL6 melanoma cell line used as the tumor model in this study is unique among mouse cell lines as it lacks a-gal epitopes. 49, 50, 52, 65 In addition, BL6 cells are among the most tumorigenic and least immunogenic tumor cells known in mice. [49] [50] [51] BL6 immunogenicity is so low that immunization with irradiated BL6 cells that secreted IL2 or GM-CSF confers no protection against challenge with live BL6 cells. 51 This low immunogenicity mimics that of human tumors that are usually selected in vivo for low immunogenicity by a continuous selective immune pressure for the elimination of tumor cells that can elicit an immune response. 12, 13 The much higher protection against BL6 tumor challenge observed in KO mice immunized with BL6 AdaGT cells than in those immunized with BL6 controlAd cells strongly suggests that a-gal epitope expression effectively increases the immunogenicity of BL6 cells. These observations further suggest that a similar increase in immunogenicity may also be achieved with autologous tumor cells of low immunogenicity that are processed as autologous tumor vaccines expressing a-gal epitopes in humans. A large number of tumor cells in humans can be obtained from patients with hematological malignancies (i.e. leukemia, lymphoma and myeloma) for the preparation of these autologous tumor vaccines. The assumption that AdaGT can induces expression of a-gal epitopes on lymphoid cells is supported by our previous studies, which demonstrated the effective expression of a-gal epitopes on normal lymphocytes obtained from KO mice. 66 We further demonstrated expression of a-gal epitopes on human cells with the HeLa carcinoma cell line transduced with AdaGT. 55 Taken together with the present study, these observations suggest that expression of a-gal epitopes may also be achieved on malignant human lymphocytes processed as autologous tumor vaccines, by similar transduction with AdaGT. 
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The demonstrated ability of anti-Gal to bind in vivo to cells expressing a-gal epitopes and to opsonize them for effective uptake by APC (Fig 4) suggests that the increased protection of the mice following immunization with BL6 AdaGT cells is associated with the anti-Galmediated phagocytosis of the immunizing cells by APC. These observations are further supported by our previous studies in which we demonstrated increased immunogenicity of a BL6 subclone that expresses a-gal epitopes following stable transfection with the a1,3GT gene. 65 Those BL6 cells were generated by transduction with a plasmid vector containing this gene and selection by a combination of antibiotics resistance and BS lectin binding for a subclone expressing this epitope. 65 Since freshly isolated tumor cells in patients are usually nondividing cells that cannot be grown in culture, stable transfection by a plasmid and subsequent selection for agal epitope expression may not be applicable for tumor cells freshly isolated for vaccine preparation. A similar selection of a-gal-positive tumor cells, after transfection with a retrovirus containing the a1,3GT gene, also requires the proliferation of the transfected cells for insertion of the gene into the genome of the cell, as previously demonstrated with human cell lines processed to express this epitope. [60] [61] [62] [63] In contrast, transduction with AdaGT results in a-gal epitope expression in a large proportion of the tumor cells (Fig 2) . Therefore, in vitro transduction with AdaGT is likely to be suitable for inducing expression of a-gal epitopes on freshly obtained tumor cells that are processed as autologous tumor vaccine.
A second possible application of AdaGT in cancer immunotherapy is the direct injection of this vector into solid tumor masses in cancer patients. Many patients with solid organ tumors relapse with multiple metastases. Injection of AdaGT into such tumor masses, as subcutaneously in melanoma patients, or into tumor masses in accessible internal sites (e.g. in the colon wall of patients with recurrent colon carcinoma) will result in the expression of a-gal epitopes on tumor cells transduced with AdaGT. This, in turn, will lead to an anti-Gal IgGmediated inflammatory reaction and extravascular destruction of these metastatic tumor cells in a manner similar to extravascular destruction of xenograft cells expressing a-gal epitopes. 38 A secondary outcome of such a process will be the internalization of the anti-Galopsonized tumor membranes by APC and their transportation to the lymph nodes, where the APC present autologous TAA peptides, and thus may elicit an antitumor immune response. 27 The exact mechanism that protects against the challenge with BL6 cells in mice immunized with irradiated BL6 AdaGT cells is under study. Several immune mechanisms may contribute to the prevention of tumor development in the challenged mice. The increased presentation of BL6 tumor antigenic peptides on class II MHC molecules of APC is likely to activate helper T cells, whereas tumor peptides presented on class I MHC molecules will activate tumor-specific cytotoxic T cells. While the cytotoxic T cells circulate in the body in order to seek and destroy the BL6 tumor cells introduced by the challenge, the activated helper T cells may enable the subsequent activation of tumor-specific cytotoxic T cells and activation of B cells producing tumor-specific antibodies. Such antibodies may contribute to protection against tumor challenge by facilitating antibody-dependent cell-mediated cytotoxicity of tumor cells and possibly complement-mediated lysis of tumor cells. Ultimately, tumor cell destruction may be the result of combined T-and B-cell immune responses. In a previous study, 65 we have studied the inflammatory cells surrounding BL6 tumors in KO mice vaccinated with BL6 cells that express a-gal epitopes following stable transfection with a1,3GT and subsequently challenged with live BL6 cells. The tumors in the vaccinated mice were surrounded by mononuclear cells comprising of B70% T cells and 30% macrophages. In the present study, it is probable that tumors are destroyed by similar mononuclear cells. Further evaluation of the antitumor-specific activity of the T cells migrating to the tumor development site will require the isolation of these cells, their in vitro expansion into CD4
þ and CD8 þ T-cell populations and the analysis of their activity toward the BL6 cells.
In conclusion, anti-Gal-mediated targeting of vaccinating AdaGT-transduced autologous tumor cells to APC fulfills a major function in enabling the vaccine to reach the lymph nodes. In the absence of a targeting mechanism of the vaccine to APC, the vaccinating tumor cells may reside in the vicinity of APC at the vaccination site, and the APC will ''ignore'' them. Previous studies on gene therapy in cancer demonstrated the recruiting of APC to the vaccination site when the vaccinating tumor cells are engineered to secrete GM-CSF. [67] [68] [69] However, since tumor cells evolve to become ''invisible'' to APC, the many APC induced by GM-CSF to migrate to the vaccination site will not effectively internalize the vaccinating tumor cells. Therefore, the gene therapy method described in the present study may complement the GM-CSF-secreting vaccine. Whereas GM-CSF recruits APC to the vaccination site, anti-Gal opsonization induces effective uptake of the vaccinating tumor cells by the recruited APC. GM-CSF production may be achieved by transduction with adenovirus containing the GM-CSF gene. By combining this APC recruitment method with the targeting to APC of vaccines expressing a-gal epitopes, the immune response to tumor antigens in autologous tumor vaccines may be maximized. Alternatively, injection of AdaGT directly into tumor masses will result in an anti-Gal-mediated inflammatory response that may lead to a similar APC transportation of anti-Gal-opsonized tumor membranes to lymph nodes.
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